Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Review of Efficacy, Safety, and Clinical Applications Authors: Marta Bajeli, Antonio Corsello, Simone Foti Randazzese, Alessia Marseglia, Paola D’Agostino, Carlo Maria Rossi, Gian Luigi Marseglia, Amelia Licari Published: 2026 ABSTRACT AbstractThis review aims to critically summarize current evidence on the biological rationale, efficacy, safety, patient selection, and clinical positioning of mepolizumab in children and adolescents with severe eosinophilic asthma. Severe eosinophilic asthma in childhood is associated with recurrent exacerbations, impaired quality of life, healthcare utilization, and cumulative corticosteroid toxicity. Mepolizumab is a humanized monoclonal antibody targeting interleukin-5 and is approved as add-on treatment for severe eosinophilic asthma in children aged 6 years and older. Pediatric pharmacokinetic and pharmacodynamic studies demonstrate profound and sustained suppression of blood eosinophils, while randomized and real-world evidence consistently supports a reduction in severe exacerbations. Available data also suggest corticosteroid-sparing effects and reduced healthcare utilization in selected patients, whereas improvements in lung function and daily symptom control are less consistent. Pediatric studies indicate a generally favorable safety and tolerability profile, although long-term pediatric-specific data remain limited. Within the current biologic treatment landscape, mepolizumab appears particularly relevant when eosinophilic inflammation, recurrent exacerbations, and corticosteroid burden represent the dominant treatable traits. However, the pediatric evidence base remains substantially smaller than that available in adults, and no head-to-head trials have directly compared mepolizumab with other biologics. Important unresolved issues include the identification of more precise predictors of response, the optimal duration of treatment, criteria for treatment withdrawal or switching, and the potential disease-modifying effects of early biologic intervention.Keywords: interleukin-5, biologics, children, exacerbations, corticosteroid-sparing, precision medicine Introduction Asthma is the most common chronic respiratory disease in childhood and remains a major cause of morbidity worldwide. Although most children achieve adequate disease control with low- to medium-dose inhaled corticosteroids (ICS), a small but clinically important subgroup continues to experience persistent symptoms, recurrent exacerbations, and impaired lung function despite intensive treatment.1 According to the European Respiratory Society (ERS) and American Thoracic Society (ATS) definition, severe asthma is asthma that remains uncontrolled despite adherence to optimized high-dose ICS plus at least one additional controller and appropriate management of contributory factors, or that requires such treatment to prevent loss of control.2 Within this framework, it is essential to distinguish difficult-to-treat asthma from severe therapy-resistant asthma (STRA). Difficult-to-treat asthma refers to persistent lack of control despite the prescription of medium- or high-dose ICS in combination with an additional controller, usually as a consequence of modifiable factors such as poor adherence, incorrect inhaler technique, comorbidities, or ongoing environmental exposures. In contrast, STRA identifies a subgroup of patients in whom symptoms and exacerbations persist despite systematic recognition and correction of these factors.3 This distinction is particularly relevant in pediatric practice, where diagnostic uncertainty, treatment adherence, and environmental influences frequently complicate the assessment of disease severity. Severe asthma accounts for only a small proportion of pediatric asthma cases, with an estimated prevalence of approximately 3% in Europe, but it is associated with a disproportionate burden of morbidity and healthcare utilization.4 Children with severe asthma frequently experience recurrent exacerbations, emergency department visits, hospitalization, impaired quality of life, and school absenteeism.5–8 Persistent airway inflammation and repeated exacerbations may also contribute to airway remodeling and impaired lung function trajectories extending into adulthood.9,10 In addition, prolonged exposure to high-dose ICS and repeated or maintenance systemic corticosteroid treatment may result in clinically relevant adverse effects, including adrenal suppression, impaired growth and bone health, metabolic complications, and neuropsychiatric effects.11,12 These considerations highlight the need for effective corticosteroid-sparing strategies in children whose disease remains uncontrolled despite optimized conventional treatment. Asthma is now widely recognized as a heterogeneous disorder rather than a single disease entity, encompassing multiple phenotypes sustained by distinct immunopathobiological mechanisms, commonly referred to as endotypes.13 Among these, the distinction between type 2 (T2)-high and T2-low asthma has become especially relevant for therapeutic decision-making.14,15 T2-high asthma, which includes eosinophilic asthma, is characterized by activation of IL-4-, IL-5-, and IL-13-driven pathways, often associated with blood and airway eosinophilia, elevated serum IgE, and increased fractional exhaled nitric oxide (FeNO).15,16 In general, T2-high disease is more responsive to corticosteroids, although a subset of patients remains inadequately controlled despite high-intensity treatment.16–18 By contrast, T2-low asthma, which may include neutrophilic or paucigranulocytic inflammatory patterns, is less well characterized in children and is typically associated with poorer responsiveness to corticosteroids.15,19 Improved understanding of asthma endotypes has led to the development of biologic therapies targeting specific inflammatory pathways involved in severe disease. Among these, mepolizumab, a humanized monoclonal antibody directed against interleukin-5 (IL-5), has emerged as an important therapeutic option for severe eosinophilic asthma. By binding circulating IL-5, mepolizumab inhibits its interaction with the IL-5 receptor on eosinophils, thereby reducing eosinophil differentiation, activation, recruitment, and survival.20 Through this mechanism, it directly targets a central effector pathway in T2-high eosinophilic airway inflammation. Mepolizumab has acquired a distinctive role in pediatric severe asthma because it is approved from 6 years of age and older and is supported by an expanding pediatric evidence base that includes pharmacokinetic and pharmacodynamic studies, a dedicated randomized controlled trial, mechanistic investigations, and real-world studies. These complementary data provide an opportunity to evaluate not only its efficacy and safety, but also the determinants of variable treatment response and the mechanisms underlying residual disease despite substantial suppression of blood eosinophils. This review aims to summarize and critically appraise the available evidence on mepolizumab in children and adolescents with severe eosinophilic asthma. Specifically, we examine its biological rationale, pharmacology, efficacy in clinical trials and real-world studies, safety profile, patient-selection criteria, biomarkers of response, and clinical positioning within a precision medicine approach to severe asthma. We also discuss the limitations of the current pediatric evidence base and identify priorities for future research. Pathophysiology of Eosinophilic Asthma Eosinophilic asthma is a distinct endotype of asthma characterized by type 2 (T2) inflammation and represents the most prevalent inflammatory pattern in severe asthma.21,22 Clinically, this endotype is commonly identified by biomarkers of T2-high inflammation, particularly elevated blood eosinophil counts and increased fractional exhaled nitric oxide (FeNO), which together support the recognition of eosinophilic airway inflammation.13 The underlying pathophysiology is driven by a complex inflammatory network in which IL-5 plays a central and relatively selective role in eosinophil biology. T2 inflammation is initiated when airway epithelial cells, in response to allergens, viral infections, pollutants, or other environmental triggers, release epithelial-derived cytokines, or “alarmins”, including thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, and IL-25.23,24 These mediators activate both adaptive and innate immune pathways, particularly T helper 2 (Th2) cells and group 2 innate lymphoid cells (ILC2s). Once activated, these cells produce the canonical T2 cytokines IL-4, IL-5, and IL-13, which exert complementary but distinct roles in asthma pathogenesis.24,25 IL-4 promotes Th2-cell differentiation and induces IgE class switching in B cells, thereby amplifying allergic sensitization. IL-13 contributes to airway hyperresponsiveness, mucus hypersecretion, and nitric oxide production through upregulation of inducible nitric oxide synthase in airway epithelial cells, resulting in increased FeNO levels.26 Although IL-4 and IL-13 share the IL-4 receptor α subunit and have overlapping biological effects, IL-5 has a more specific role in eosinophil development, activation, and survival, making it a pivotal cytokine in eosinophilic asthma.26,27 The Central Role of IL-5 IL-5 is the principal cytokine regulating eosinophil homeostasis across their entire life cycle. At the bone marrow level, it promotes terminal differentiation and maturation of eosinophils from CD34+ progenitor cells.27,28 In cooperation with eotaxins, particularly CCL11, IL-5 also facilitates the mobilization of mature eosinophils and eosinophil precursors into the peripheral circulation.28 Once released into the bloodstream, eosinophils are primed by IL-5 for enhanced survival, increased cytotoxic potential, and greater responsiveness to chemotactic and inflammatory stimuli. Experimental data indicate that IL-5 activates multiple intracellular signaling pathways involved in eosinophil priming and function, including phosphatidylinositol-3-kinase (PI3K), extracellular signal-regulated kinase (ERK), and p38 mitogen-activated protein kinase (MAPK) pathways.29 Through these mechanisms, IL-5 enhances eosinophil migration to inflamed tissues, promotes activation within the airway microenvironment, and inhibits apoptosis, thereby sustaining tissue eosinophilia and chronic airway inflammation.30 Beyond its direct effects on eosinophils, IL-5 may also influence other cell populations involved in T2 inflammation, including mast cells, basophils, ILC2s, epithelial cells, and fibroblasts, suggesting a broader role in the orchestration of airway inflammatory responses.31 Eosinophils as Effector Cells in Severe Asthma Eosinophils are bone marrow-derived granulocytes of the myeloid lineage.32–36 After their release into the circulation, they remain in the bloodstream only briefly before migrating to peripheral tissues, particularly epithelial surfaces such as the respiratory and gastrointestinal tracts, where the vast majority of eosinophils reside under homeostatic conditions.36,37 In healthy individuals, eosinophils account for approximately 1–5% of circulating leukocytes, with normal peripheral blood counts generally ranging from 100 to 500 cells/μL.37 Accumulating evidence suggests that eosinophils are not a homogeneous population but comprise functionally distinct subsets.38–41 Two major populations have been described in both murine models and humans: resident eosinophils (rEos) and inflammatory eosinophils (iEos).40 Resident eosinophils appear to exert immunoregulatory and tissue-supportive functions, including modulation of dendritic cell activity, attenuation of Th2 responses to inhaled allergens, participation in epithelial repair, and extracellular matrix turnover.42–44 Outside the airways, eosinophils also contribute to metabolic homeostasis, tissue regeneration, plasma cell maintenance, and possibly antitumor immunity.45–47 By contrast, inflammatory eosinophils are recruited to the airways during allergic and eosinophilic inflammation and are thought to be the main population responsible for tissue injury and disease exacerbation.48,49 CD62L (L-selectin) has emerged as one of the surface markers that may help distinguish these populations, as resident eosinophils generally express higher levels of CD62L, whereas inflammatory eosinophils show lower CD62L expression together with a more activated phenotype.50 Once recruited to the airways, activated eosinophils act as major effector cells contributing to epithelial damage, airway dysfunction, and structural remodeling. Through degranulation and cytolysis, they release a range of cytotoxic mediators, including major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and eosinophil-derived neurotoxin (EDN), all of which can damage the respiratory epithelium, impair mucociliary function, and promote epithelial shedding.45,50 Eosinophils also generate reactive oxygen species and release cysteinyl leukotrienes (LTC4, LTD4, and LTE4), potent mediators of bronchoconstriction, mucus secretion, and airway edema.36 In addition, they can undergo lytic cell death with the formation of eosinophil extracellular traps (EETs) and release a broad repertoire of cytokines and growth factors, including IL-4, IL-5, IL-13, transforming growth factor-β (TGF-β), and granulocyte-macrophage colony-stimulating factor (GM-CSF), thereby amplifying both innate and adaptive inflammatory responses.45,50 Collectively, these mechanisms contribute not only to acute airway inflammation and exacerbations, but also to chronic airway remodeling, including subepithelial fibrosis, goblet cell metaplasia, and smooth muscle hyperplasia.42 Taken together, these observations support the concept that eosinophils are not merely biomarkers of T2-high asthma, but active pathogenic effectors in a substantial proportion of children with severe disease. The central role of IL-5 in eosinophil differentiation, activation, and persistence provides the biological rationale for targeted anti-IL-5 therapies such as mepolizumab. Mepolizumab: Mechanism of Action, Pharmacology, and Clinical Indications Mepolizumab is a humanized monoclonal antibody of the IgG1 kappa subclass that selectively targets interleukin-5 (IL-5), a pivotal cytokine in type 2 inflammation and the principal regulator of eosinophil proliferation, maturation, activation, and survival. By binding circulating IL-5 with high affinity and specificity, mepolizumab prevents its interaction with the alpha subunit of the IL-5 receptor (IL-5Rα) expressed on eosinophils, thereby reducing eosinophil maturation, recruitment, activation, and persistence in both the bloodstream and airway tissues.51 Unlike benralizumab, which targets IL-5Rα and promotes eosinophil depletion through antibody-dependent cell-mediated cytotoxicity, mepolizumab acts by neutralizing circulating IL-5 rather than by directly inducing eosinophil apoptosis. This mechanistic distinction is relevant when considering the different biologic strategies currently available for severe eosinophilic asthma.51 From a pharmacologic perspective, mepolizumab is administered by subcutaneous injection every 4 weeks. According to the current FDA prescribing information, it is indicated as add-on maintenance treatment for adult and pediatric patients aged 6 years and older with severe asthma and an eosinophilic phenotype. The EMA product information similarly authorizes mepolizumab as add-on treatment for severe refractory eosinophilic asthma in adults, adolescents, and children aged 6 years and older.52,53 Current FDA and EMA indications and dosing recommendations for mepolizumab in severe eosinophilic asthma are summarized in Table 1. Table 1FDA and EMA Approval Status of Mepolizumab for Severe Eosinophilic AsthmaParameterFDAEMAIndicationAdd-on maintenance treatment for adult and pediatric patients aged ≥6 years with severe asthma and an eosinophilic phenotypeAdd-on treatment for severe refractory eosinophilic asthma in adults, adolescents, and children aged ≥6 yearsApproved age≥6 years≥6 yearsDose in children aged 6–11 years40 mg SC every 4 weeks40 mg SC every 4 weeksDose in patients aged ≥12 years100 mg SC every 4 weeks100 mg SC every 4 weeksRoute/frequencySubcutaneous administration every 4 weeksSubcutaneous administration every 4 weeksHome administrationIn children aged 6–11 years, the 40 mg prefilled syringe may be administered by a caregiver or a healthcare professional; in patients aged ≥12 years, approved devices allow self-administration or caregiver administrationAccording to the authorized product information and approved presentation/use conditionsNotes: Summary of current FDA and EMA indications and dosing recommendations for mepolizumab in severe eosinophilic asthma.52,53 Bold type denotes column headings. ≥, greater than or equal to; <, less than.Abbreviations: EMA, European Medicines Agency; FDA, Food and Drug Administration; SC, subcutaneous. FDA and EMA Approval Status of Mepolizumab for Severe Eosinophilic Asthma Notes: Summary of current FDA and EMA indications and dosing recommendations for mepolizumab in severe eosinophilic asthma.52,53 Bold type denotes column headings. ≥, greater than or equal to; <, less than. Abbreviations: EMA, European Medicines Agency; FDA, Food and Drug Administration; SC, subcutaneous. Regulatory wording differs slightly between agencies. The FDA labeling frames the indication as “severe asthma with an eosinophilic phenotype”, whereas the EMA uses the term “severe refractory eosinophilic asthma.” In practice, both definitions identify patients with uncontrolled severe disease despite optimized background therapy and evidence of eosinophilic inflammation, generally supported by recurrent exacerbations and elevated blood eosinophil counts. Within the pediatric severe asthma treatment pathway, mepolizumab should be considered after the diagnosis of severe therapy-resistant asthma has been confirmed and modifiable causes of poor disease control, including suboptimal adherence, incorrect inhaler technique, ongoing environmental exposures, and untreated comorbidities, have been systematically addressed. It is particularly relevant for children and adolescents with a clear eosinophilic phenotype in whom recurrent exacerbations and cumulative corticosteroid exposure remain the dominant clinical problems despite optimized inhaled therapy. When more than one biologic treatment is potentially suitable, the choice between mepolizumab and other targeted add-on therapies should be individualized according to the patient’s phenotype, biomarker profile, relevant comorbidities, approved age range, previous treatment response, and principal therapeutic goals. For asthma, the approved dose in the FDA label is 40 mg subcutaneously every 4 weeks for children aged 6–11 years and 100 mg every 4 weeks for patients aged 12 years and older. In the EMA product information, the recommended dose is likewise 40 mg every 4 weeks for children aged 6–11 years and 100 mg every 4 weeks for patients aged 12 years and older. FDA labeling also documents that the 40 mg prefilled syringe may be administered by a caregiver or a healthcare professional in children aged 6–11 years, whereas patients aged 12 years and older may self-administer or receive caregiver administration using the approved devices.52,53 As with other monoclonal antibodies, mepolizumab is degraded by widely distributed proteolytic enzymes rather than through a specific hepatic metabolic pathway. Following subcutaneous administration, its bioavailability is approximately 80%, and the mean terminal half-life is about 16 to 22 days in the FDA prescribing information, supporting the 4-week dosing interval.52,53 Beyond asthma, the approved indications and age ranges are not fully superimposable between FDA and EMA. Both agencies currently include chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic obstructive pulmonary disease (COPD) in adults, whereas differences remain in the approved populations for eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES).52,53 Key Clinical Studies of Mepolizumab in Pediatric Severe Eosinophilic Asthma Pivotal Studies The clinical development of mepolizumab in pediatric severe eosinophilic asthma has followed a bridging strategy, in which adult and adolescent efficacy data were complemented by pediatric pharmacokinetic, pharmacodynamic, safety, and, later, randomized efficacy data. The currently available evidence is summarized in Table 2. Table 2Key Pediatric Studies of Mepolizumab in Severe Eosinophilic AsthmaA. Clinical Efficacy and Safety StudiesStudyDesignPopulation (Age)Treatment/DurationPrimary Endpoint(s)Key FindingsLimitationsGupta et al, 2019 (Part A)54Multinational, non-randomized, open-label, Phase 2 PK/PD study (NCT02377427)36 children with severe eosinophilic asthma, 6–11 yearsSC mepolizumab every 4 weeks for 12 weeks; 40 mg if <40 kg, 100 mg if ≥40 kgPharmacokinetics and pharmacodynamicsExposure was within twofold of target adult exposure; blood eosinophils were reduced by 89% and 83% in the two weight-based groups; tolerability was favorable with no new safety signalsSmall sample size; no comparator arm; short duration; not powered for efficacy outcomesGupta et al, 2019 (Part B)55Open-label, uncontrolled, repeat-dose extension of Part A (NCT02377427)30 children continuing from Part A, 6–11 yearsSC mepolizumab every 4 weeks for 52 weeks; body weight–dependent dosingLong-term safety and immunogenicity; secondary PD; exploratory efficacyNo treatment-related serious adverse events; no anti-drug or neutralizing antibodies detected; sustained eosinophil suppression; reductions in exacerbations and improvement in asthma control were observedOpen-label extension; no control group; efficacy outcomes exploratory; limited external generalizabilityJackson et al, 2022 (MUPPITS-2)56Randomized, double-blind, placebo-controlled, parallel-group trial290 children/adolescents with exacerbation-prone eosinophilic asthma, 6–17 yearsSC mepolizumab plus guideline-based care vs placebo for 52 weeks; 40 mg for 6–11 years, 100 mg for 12–17 yearsNumber of exacerbations treated with systemic corticosteroids during 52 weeksAnnualized exacerbations were reduced versus placebo (0.96 vs 1.30; rate ratio 0.73); this established pediatric RCT efficacy, although the magnitude of benefit was smaller than typically reported in adultsEffect size more modest than in adult trials; limited improvement in some physiological secondary outcomes; population enriched for a specific high-risk urban phenotypeB. Mechanistic companion studiesStudyDesignPopulationMechanistic approachKey findingsClinical relevanceLimitationsWilson et al, 2024 (SCOUT substudy)57Mechanistic substudy nested within MUPPITS-253 MUPPITS-2 participantsInduced sputum analysis with high-dimensional mass cytometry (CyTOF)Mepolizumab reduced median sputum eosinophils; three eosinophil subpopulations were identified according to CD62L expression; CD62L^int and CD62L^hi eosinophils were enriched in mepolizumab-treated children with breakthrough exacerbationsSuggests that persistent activated airway eosinophil subsets may contribute to residual disease despite blood eosinophil suppressionSmall substudy; airway-specific mechanistic findings; hypothesis-generating rather than definitive for clinical decision-makingAltman et al, 202558Secondary analysis of MUPPITS-2108 participants sampled during 176 acute respiratory illness eventsNasal transcriptomic modular analysis during illness episodesResidual exacerbations during mepolizumab treatment were associated with increased epithelial and macrophage inflammatory pathway expression despite suppression of canonical eosinophil/T2 signaturesProvides a molecular explanation for incomplete clinical response and supports the concept of alternative non-T2 inflammatory drivers in breakthrough exacerbationsSecondary analysis; subset of parent trial; findings are mechanistic and require external validationGaberino et al, 202559Secondary systems-biology analysis of MUPPITS-2Paired nasal transcriptomic samples from children/adolescents in the mepolizumab and placebo armsDifferential gene correlation analysis of inflammatory gene networksMepolizumab disrupted correlation among eosinophil-specific genes but preserved or strengthened networks related to mast cells, T2 cytokines, and epithelial inflammationSupports the view that treatment response depends not only on eosinophil depletion but also on persistence of parallel inflammatory networksTranslational analysis; biomarker implications remain exploratory; not directly sufficient to guide routine treatment selectionNotes: Key pediatric studies of mepolizumab, organized into clinical efficacy and safety studies and mechanistic companion studies. Bold type denotes column headings. <, less than; ≥, greater than or equal to; %, percentage. Superscript “int” and “hi” indicate intermediate and high CD62L expression, respectively. Superscript Arabic numerals denote reference citations.Abbreviations: CyTOF, cytometry by time-of-flight; PD, pharmacodynamics; PK, pharmacokinetics; RCT, randomized controlled trial; SC, subcutaneous. Key Pediatric Studies of Mepolizumab in Severe Eosinophilic Asthma Notes: Key pediatric studies of mepolizumab, organized into clinical efficacy and safety studies and mechanistic companion studies. Bold type denotes column headings. <, less than; ≥, greater than or equal to; %, percentage. Superscript “int” and “hi” indicate intermediate and high CD62L expression, respectively. Superscript Arabic numerals denote reference citations. Abbreviations: CyTOF, cytometry by time-of-flight; PD, pharmacodynamics; PK, pharmacokinetics; RCT, randomized controlled trial; SC, subcutaneous. The first dedicated pediatric study was the multinational phase 2 trial by Gupta et al, conducted in children aged 6–11 years with severe eosinophilic asthma.54,55 In Part A, 36 children received subcutaneous mepolizumab every 4 weeks for 12 weeks, using body weight–based dosing of 40 mg for those weighing less than 40 kg and 100 mg for those weighing 40 kg or more. The study was primarily designed to characterize pharmacokinetics and pharmacodynamics rather than clinical efficacy. Importantly, mepolizumab exposure in children remained within twofold of target adult exposure despite somewhat higher-than-predicted bioavailability, and treatment was associated with marked blood eosinophil suppression, with reductions of 89% and 83% in the two dose groups and nadir values of 42 and 55 cells/µL, respectively.54 Early safety findings were reassuring, with no new safety signals, no cases of anaphylaxis, and only infrequent transient anti-drug antibodies without neutralizing activity. Although efficacy outcomes were exploratory, the study also showed a trend toward improvement in asthma control, while changes in lung function were less clear. These findings were extended in Part B of the same program, an open-label 52-week extension study involving 30 children who had completed Part A. Long-term treatment confirmed sustained suppression of blood eosinophils, with counts again decreasing to approximately 50 cells/µL after treatment re-initiation. Safety remained favorable and consistent with that previously observed in adults and adolescents: although most children experienced at least one adverse event and 23% experienced a serious adverse event, none of the serious events were considered treatment-related, and no anti-drug or neutralizing antibodies were detected during the extension phase.55 Exploratory efficacy outcomes were also encouraging. The annualized exacerbation rate fell to 1.09 events per year, and 80% of children achieved at least a 50% reduction in exacerbations compared with baseline. Asthma control also improved over time, with reductions in ACQ scores and improvement in childhood asthma control measures, supporting a favorable benefit-risk profile in this age group. Nevertheless, the open-label, uncontrolled design and limited sample size mean that these results should be interpreted as supportive rather than definitive evidence of efficacy. The strongest pediatric efficacy data currently come from MUPPITS-2, the first randomized, double-blind, placebo-controlled trial of mepolizumab conducted specifically in children and adolescents with exacerbation-prone eosinophilic asthma.56 In this study, Jackson et al randomized 290 children and adolescents aged 6–17 years from nine urban US medical centers to receive mepolizumab or placebo every 4 weeks for 52 weeks in addition to guideline-based care. The trial enrolled a high-risk population, predominantly comprising Black and Hispanic children and adolescents from socioeconomically disadvantaged urban communities, thereby addressing an important evidence gap in populations disproportionately affected by asthma morbidity. Mepolizumab reduced the annualized number of exacerbations requiring systemic corticosteroids from 1.30 in the placebo group to 0.96 in the active-treatment group, corresponding to a rate ratio of 0.73.56 These findings provided controlled evidence of the efficacy of mepolizumab in pediatric eosinophilic asthma. However, the magnitude of benefit was more modest than the approximately 50% reduction in exacerbations reported in several adult trials. This difference should be interpreted cautiously as it derives from indirect comparisons across studies with different populations, eligibility criteria, baseline risks, background treatments, and outcome definitions, and should not be regarded as evidence of intrinsically lower pharmacological efficacy in children. The distinctive clinical and sociodemographic characteristics of the MUPPITS-2 population may have contributed to the observed effect size.56 Environmental and social determinants, including housing-related allergen exposure, air pollution, tobacco-smoke exposure, psychosocial stressors, barriers to continuity of care, and variability in treatment adherence, may sustain exacerbation risk through mechanisms that are not fully dependent on IL-5-mediated eosinophilic inflammation. In addition, pediatric exacerbations are frequently precipitated by respiratory infections and may involve epithelial, macrophage-associated, mucus-related, and other inflammatory pathways that persist despite substantial suppression of circulating eosinophils. These factors may partly explain the more modest treatment effect observed in MUPPITS-2, although the trial was not designed to quantify their individual contributions. Overall, the findings indicate that mepolizumab provides clinically meaningful protection against exacerbations in children while highlighting the multifactorial nature of residual disease activity in pediatric severe asthma. Mechanistic Companion Studies A major strength of the pediatric mepolizumab literature is that MUPPITS-2 was accompanied by a series of mechanistic studies that help explain why some children continue to exacerbate despite effective IL-5 blockade. These analyses are especially relevant in a pediatric review because they suggest that blood eosinophil suppression, although biologically robust, does not fully capture residual airway inflammatory activity.57–59 In the SCOUT substudy, Wilson et al applied high-dimensional mass cytometry to induced sputum samples from 53 MUPPITS-2 participants and identified three distinct eosinophil subpopulations based on CD62L expression. Overall, mepolizumab reduced median sputum eosinophils by 58% compared with placebo, confirming an effect on airway eosinophilic inflammation. However, among children treated with mepolizumab, those who continued to experience exacerbations showed relative enrichment of CD62L^int and CD62L^hi eosinophil populations, which were characterized by a more activated phenotype.57 These findings suggest that residual airway eosinophils are heterogeneous and that persistent activated eosinophil subsets may contribute to breakthrough exacerbations despite substantial suppression of circulating eosinophils. Transcriptomic analyses have provided a complementary view of residual disease mechanisms. In a secondary analysis of MUPPITS-2, Altman et al examined nasal transcriptomic signatures during acute respiratory illnesses and showed that, during exacerbations occurring under mepolizumab treatment, canonical eosinophil-associated type 2 inflammation was blunted, whereas several alternative inflammatory pathways became more prominent.58 In particular, exacerbations during mepolizumab therapy were associated with increased expression of epithelial and macrophage-related inflammatory modules, as well as mucus hypersecretion and stress-response pathways.58 Epithelial inflammatory programs appeared relevant across both viral and non-viral exacerbations, whereas macrophage-associated pathways were particularly linked to viral events. These data provide a molecular explanation for the attenuated but incomplete protection afforded by mepolizumab in children, especially in a population highly exposed to respiratory viral triggers. Gaberino et al further expanded this framework by applying differential gene correlation analysis to paired nasal transcriptomic samples from MUPPITS-2.59 Rather than focusing solely on changes in gene expression, this analysis explored how mepolizumab reshaped the internal regulatory architecture of airway inflammatory networks. Treatment led to loss of correlation among eosinophil-specific genes, but conservation or even strengthening of correlation among mast cell-related genes, type 2 cytokine networks, and epithelial inflammatory pathways. Notably, strengthening of epithelial-associated networks, including modules linked to extracellular matrix production and nitric oxide synthesis, was associated with poorer clinical response.59 These results suggest that mepolizumab not only suppresses eosinophilic inflammation but may also reveal persistent parallel networks that continue to sustain disease activity in some children. Integrated Interpretation of the Evidence Taken together, the available pediatric studies support a consistent view of mepolizumab as an effective biologic therapy for children and adolescents with severe eosinophilic asthma, particularly for the prevention of exacerbations. The early PK/PD studies established that pediatric dosing achieves biologically meaningful exposure and profound eosinophil suppression, while long-term extension data supported acceptable tolerability and sustained pharmacodynamic activity. MUPPITS-2 subsequently confirmed clinical efficacy in a randomized setting, but also showed that the magnitude of benefit in children may be less pronounced than in adults.54–59 Importantly, the companion mechanistic studies indicate that incomplete response should not be interpreted simply as treatment failure, but rather as evidence of the biological complexity of pediatric severe asthma. Residual airway eosinophil heterogeneity, persistent epithelial activation, macrophage-associated inflammatory programs, and maintained non-eosinophilic gene networks all appear to contribute to breakthrough exacerbations.57–59 These findings support a more nuanced interpretation of treatment response in children and reinforce the need for biomarker refinement, compartment-specific assessment of inflammation, and possibly combination or sequential biologic strategies in selected patients. Real-World Evidence Studies Real-world evidence on mepolizumab in children and adolescents with severe eosinophilic asthma remains more limited than the corresponding adult literature, but it is steadily expanding and provides an important complement to clinical trial data. In contrast to randomized studies, real-world cohorts include patients with broader phenotypic heterogeneity, variable adherence, complex comorbidity profiles, and prior exposure to other biologics. These features make such studies particularly informative for understanding how mepolizumab performs in routine clinical practice. Selected real-world studies are summarized in Table 3.60–63 Table 3Selected Real-World Studies of Mepolizumab in Pediatric Severe Eosinophilic AsthmaStudySetting/DesignPopulationFollow-UpOutcomesKey MessageLimitationsWetzke et al, 202260German multicenter retrospective real-world survey across six pediatric centers18 patients with severe pediatric asthma, ≤18 yearsMean treatment duration 12.3 months; outcomes typically assessed after initiation and over available follow-upBlood eosinophils, FEV1, exacerbation rate, physician-rated response, treatment discontinuationMepolizumab markedly reduced eosinophils and improved FEV1, but exacerbation reduction was not significant overall and discontinuation was frequent, highlighting heterogeneous clinical responseVery small sample; retrospective design; non-standardized outcome assessment; variable follow-up; substantial discontinuation limits interpretationLim et al, 202461Single-center retrospective study (Glasgow, UK)16 children/adolescents with severe eosinophilic asthma, 7–17 years, ineligible for or unresponsive to omalizumab12 months before vs 12 months after mepolizumab initiationHospital admissions, daily steroid dose, total steroid burden, ACT, FEV1, FEF25–75, FeNO, eosinophilsMepolizumab reduced hospital admissions, lowered daily oral corticosteroid requirements in a steroid-dependent subgroup, and reduced eosinophil counts, supporting usefulness in difficult-to-treat patients after omalizumab failure/ineligibilitySmall sample; retrospective single-center design; no comparator group; limited power for lung function and symptom-score changes; highly selected populationLiu et al, 2025 (SPACE registry)62Multicenter European observational registry of children already receiving biologics250 children/adolescents with severe asthma; 21.6% on mepolizumabCross-sectional enrollment snapshotAsthma control, CASI, exacerbations, unscheduled attendances, hospital admissions, biologic switchingMost children on biologics had good symptom control, but many still had exacerbations and a substantial minority had switched biologics, indicating persistent unmet need despite targeted treatmentRegistry not designed as a mepolizumab-only effectiveness study; cross-sectional structure; heterogeneity in biologic choice and national access criteria; confounding by indicationHernandez et al, 202563US retrospective administrative claims analysis580 children and adolescents with severe asthma, 6–17 years12 months before vs 12 months after mepolizumab initiationExacerbations, OCS dispensings and bursts, SABA use, asthma-related and all-cause HCRUMepolizumab initiation was associated with reduced overall exacerbations, OCS use, and healthcare utilization, supporting real-world clinical benefit at scaleRetrospective claims design; diagnosis and outcomes based on coding; no direct biomarker, lung function, or symptom-control data; residual confounding possibleNotes: Selected real-world studies evaluating mepolizumab in pediatric severe eosinophilic asthma or in severe pediatric asthma cohorts including mepolizumab-treated patients. Bold type denotes column headings. ≤, less than or equal to; %, percentage. Superscript Arabic numerals denote reference citations.Abbreviations: ACT, Asthma Control Test; CASI, Composite Asthma Severity Index; FEF25–75, forced expiratory flow at 25–75% of forced vital capacity; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; HCRU, healthcare resource utilization; OCS, oral corticosteroids; SABA, short-acting β2-agonist; SPACE, Severe Paediatric Asthma Collaborative in Europe. Selected Real-World Studies of Mepolizumab in Pediatric Severe Eosinophilic Asthma Notes: Selected real-world studies evaluating mepolizumab in pediatric severe eosinophilic asthma or in severe pediatric asthma cohorts including mepolizumab-treated patients. Bold type denotes column headings. ≤, less than or equal to; %, percentage. Superscript Arabic numerals denote reference citations. Abbreviations: ACT, Asthma Control Test; CASI, Composite Asthma Severity Index; FEF25–75, forced expiratory flow at 25–75% of forced vital capacity; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; HCRU, healthcare resource utilization; OCS, oral corticosteroids; SABA, short-acting β2-agonist; SPACE, Severe Paediatric Asthma Collaborative in Europe. Among the earliest pediatric real-world reports, Wetzke et al described multicenter experience from six pediatric centers in Germany, including 18 patients aged 18 years or younger treated with mepolizumab. In this retrospective cohort, treatment was associated with a marked reduction in blood eosinophilia and a statistically significant improvement in FEV1 after initiation.60 However, exacerbation rates did not decrease significantly overall, and treatment discontinuation was frequent, occurring in more than half of the cohort. The most common reason for discontinuation was perceived lack of effectiveness, although possible treatment-related complaints were also documented in a substantial proportion of patients.60 Although limited by small numbers, retrospective data collection, variable follow-up, and non-standardized assessment of response, this study is important because it illustrates the heterogeneity of real-world pediatric outcomes and highlights that biologic success cannot be inferred from eosinophil suppression alone. A more focused single-center experience was subsequently reported by Lim et al in Glasgow, who evaluated 16 children and adolescents with severe eosinophilic asthma who were either ineligible for or unresponsive to omalizumab. Over the 12 months following mepolizumab initiation, asthma-related hospital admissions declined significantly, daily oral corticosteroid requirements were reduced in a clinically relevant subset of steroid-dependent patients, and blood eosinophil counts fell substantially. By contrast, changes in ACT score, lung function, FeNO, and overall oral corticosteroid burden were not statistically significant. No serious adverse reactions were reported.61 This study is particularly informative because it reflects a clinically challenging population in whom anti-IgE therapy was either unsuitable or ineffective, thereby supporting the role of mepolizumab as a useful alternative in selected children with severe eosinophilic disease. At the same time, the retrospective single-center design and small sample size limit the generalizability of the findings. A broader European perspective is provided by the Severe Paediatric Asthma Collaborative in Europe (SPACE) registry, reported by Liu et al.62 This multicenter observational registry included 250 children and adolescents receiving biologics, of whom 21.6% were treated with mepolizumab. Although the registry was not designed as a mepolizumab-only effectiveness study, it provides valuable information on the real-world landscape of pediatric biologic use. Most children on biologics achieved good symptom control, yet a considerable proportion remained partly controlled or uncontrolled according to GINA criteria, and exacerbations remained common. In addition, 16% had switched from a previous biologic, most often because of nonresponse. These findings suggest that, even in specialized centers and despite the availability of targeted therapies, substantial unmet need persists in pediatric severe asthma.62 For the present review, the SPACE registry is especially useful because it contextualizes mepolizumab within a broader treatment pathway in which switching and partial response are increasingly recognized components of routine care. The largest available pediatric real-world dataset comes from the US claims-based analysis by Hernandez et al, which included 580 children and adolescents aged 6–17 years with severe asthma evaluated before and after mepolizumab initiation.63 This study demonstrated consistent reductions across multiple clinically relevant domains. Overall asthma exacerbations decreased by 34%, oral corticosteroid dispensings by 24%, and oral corticosteroid bursts by 29% after treatment initiation. Asthma-related healthcare resource utilization also declined, including inpatient, emergency department, and outpatient visits. Because these findings were observed in a large and demographically diverse cohort, they strongly support the real-world effectiveness of mepolizumab in reducing not only exacerbation burden but also downstream healthcare use.63 However, as with all administrative claims analyses, the study is limited by its retrospective design, reliance on coding accuracy, lack of biomarker and lung function data, and inability to directly assess symptom control or physician-assigned treatment response. Taken together, these real-world studies confirm that mepolizumab is an effective maintenance therapy for many children and adolescents with severe eosinophilic asthma, particularly with regard to exacerbation reduction, corticosteroid sparing, and mitigation of healthcare utilization. At the same time, they make clear that response remains heterogeneous across cohorts and outcomes. Improvements in blood eosinophilia are consistent, but gains in lung function, symptom control, and treatment persistence are less uniform. This variability likely reflects differences in baseline phenotype, environmental burden, comorbidities, previous biologic exposure, and the contribution of inflammatory pathways not fully suppressed by IL-5 blockade. Viewed alongside the mechanistic insights derived from MUPPITS-2, the real-world literature supports a model in which mepolizumab provides substantial benefit for many children, but not complete disease control for all, reinforcing the need for individualized follow-up and more refined predictors of response. Efficacy: Synthesis of Evidence The available evidence supports mepolizumab as an effective add-on therapy for children and adolescents with severe eosinophilic asthma, with the most consistent benefit observed in the reduction of severe exacerbations. This effect is supported across the full spectrum of available evidence, including early pediatric PK/PD and extension studies, the pivotal MUPPITS-2 randomized trial, and subsequent real-world cohorts.54–63 Clinically meaningful reductions in exacerbations have also been reported in pediatric and adolescent studies of other biologic therapies for severe asthma. However, numerical differences across trials should be interpreted cautiously and cannot establish comparative superiority, given substantial heterogeneity in study populations, biomarker-based eligibility criteria, baseline exacerbation risk, background therapy, and outcome definitions. Despite some variability across studies, the overall signal for mepolizumab is clinically meaningful, particularly in patients with recurrent exacerbations despite optimized background therapy. A second strength of mepolizumab is its clear biologic activity on the IL-5/eosinophil axis. Across pediatric studies, treatment consistently produces profound suppression of blood eosinophils, confirming effective target engagement and pharmacodynamic activity in children comparable to that observed in older populations. This biologic effect is mirrored in clinical practice by reductions in oral corticosteroid exposure and, in broader real-world datasets, by decreases in asthma-related healthcare utilization.54–63 From a pediatric perspective, this corticosteroid-sparing effect is especially relevant, given the cumulative consequences of repeated or chronic steroid exposure on growth, bone health, metabolic profile, and psychological well-being. By contrast, the impact of mepolizumab on lung function and day-to-day symptom control appears less consistent. While some real-world studies have reported improvement in FEV1 or reductions in hospital admissions, randomized pediatric data have not shown similarly uniform gains across physiologic or composite clinical measures.54–63 This discrepancy likely reflects differences in study design, baseline severity, follow-up duration, sample size, and the clinical domains captured by each outcome measure. In children, spirometry may also be a less sensitive marker of treatment response than exacerbation burden, particularly when persistent symptoms are influenced by multiple overlapping inflammatory and non-inflammatory mechanisms. Importantly, the available evidence also shows that eosinophil depletion does not necessarily translate into complete disease control. Mechanistic analyses derived from MUPPITS-2 indicate that residual exacerbations during mepolizumab treatment may be driven by persistent airway eosinophil subsets, epithelial inflammatory programs, macrophage-associated pathways, and maintained non-eosinophilic gene networks. These findings help explain why some children experience only partial clinical benefit despite marked reductions in circulating eosinophils and support the view that mepolizumab is highly effective for a specific component of pediatric severe asthma, but does not fully suppress all biologic drivers of disease in every patient.56–59 Overall, the current evidence positions mepolizumab as a valuable precision therapy for selected pediatric patients with severe eosinophilic asthma, particularly when recurrent exacerbations and corticosteroid burden are the dominant clinical problems. Its greatest benefit appears to lie in stabilizing exacerbation-prone disease rather than in producing uniform improvement across all functional and symptomatic domains. Accordingly, treatment response in children should be assessed using a multidimensional framework that prioritizes exacerbations, steroid exposure, healthcare utilization, and patient-relevant clinical outcomes, rather than relying solely on lung function or blood eosinophil counts. Safety: Synthesis of Evidence Overall, the available evidence indicates that mepolizumab has a favorable safety and tolerability profile in children and adolescents with severe eosinophilic asthma. Across pediatric clinical trials, extension studies, and real-world reports, most adverse events have been mild to moderate in severity, and no major pediatric-specific safety signals have emerged to date. This consistency across different study designs is reassuring, particularly given the relatively limited size of the pediatric evidence base compared with adults. Available pediatric and adolescent studies of other biologic therapies for severe asthma have likewise reported generally favorable tolerability profiles. However, indirect comparisons are insufficient to establish clinically meaningful differences in overall safety between biologic classes, particularly with regard to rare adverse events and prolonged treatment exposure.54–63 The phase 2 pediatric program by Gupta et al provided the earliest direct evidence supporting the safety of mepolizumab in children aged 6–11 years. In Part A, short-term treatment was well tolerated and no new safety signals were identified. In the 52-week extension study, although most children experienced at least one adverse event and serious adverse events were reported in a minority, none of the serious events were considered treatment related, no fatal adverse events occurred, and no anti-drug or neutralizing antibodies were detected.54,55 Taken together, these findings support the view that prolonged exposure in younger children is associated with a safety profile broadly comparable to that already established in adults and adolescents. The randomized MUPPITS-2 trial further strengthened this assessment by evaluating mepolizumab in a larger cohort of children and adolescents under controlled conditions. Although treatment-emergent adverse events were reported more frequently in the mepolizumab group than in the placebo group, no deaths were attributed to treatment, and the overall safety findings did not reveal unexpected concerns. Importantly, this trial enrolled a clinically vulnerable urban pediatric population with high asthma morbidity, suggesting that mepolizumab remains acceptably tolerated even in patients with substantial baseline disease burden and environmental risk.56 Real-world studies broadly support this favorable safety profile, although they also illustrate the complexity of interpreting tolerability in routine care. In the Glasgow cohort reported by Lim et al, no serious adverse reactions were observed, and the only reported treatment-related events were mild injection-site reactions that resolved with oral antihistamines.61 By contrast, the German multicenter experience reported by Wetzke et al described a higher frequency of newly reported complaints, including headache, fatigue, dissociative symptoms, aphthous stomatitis, and worsening rhinitis, especially among children who ultimately discontinued treatment.60 These observations do not necessarily establish causality, but they emphasize that treatment tolerability in real life is shaped not only by biologic toxicity itself, but also by patient perception, comorbidity burden, and expectations of benefit. Additional reassurance comes from a long-term open-label extension study reporting cumulative mepolizumab exposure of up to approximately 10 years.64 This study is highly informative for the overall long-term safety profile of mepolizumab, but it should be interpreted primarily as adult-dominant evidence, since the cohort was largely composed of adults and only a small minority of participants were pediatric or adolescent. Across 514 patients, no new safety signals emerged, treatment-related serious adverse events were rare, infections were the most common serious adverse events of special interest, and physician-assessed benefit-risk remained favorable over time.64 Importantly, although pediatric/adolescent patients were included, their numbers were too small to allow robust pediatric-specific long-term safety conclusions. Therefore, this study strengthens confidence in the durability of mepolizumab safety overall, while only indirectly supporting pediatric practice. Another important aspect of safety is immunogenicity. The available pediatric trial data suggest low immunogenic potential, with no neutralizing antibody development detected in the Gupta extension study.54,55 This is clinically relevant because it supports sustained biologic activity over time and reduces concerns regarding secondary loss of effect due to antibody-mediated interference. However, because pediatric cohorts remain relatively small, rare immunologic events cannot yet be completely excluded. From a broader clinical perspective, the safety of mepolizumab should also be interpreted in relation to the risks of the disease it is intended to treat and the toxicities of the therapies it may help spare. In children with severe eosinophilic asthma, repeated or chronic oral corticosteroid exposure carries substantial long-term consequences. Therefore, a biologic with a favorable tolerability profile and meaningful corticosteroid-sparing potential may provide a net safety advantage even when minor treatment-emergent adverse events occur. In this sense, the safety profile of mepolizumab is best understood not in isolation, but within the overall risk-benefit balance of pediatric severe asthma management. Nevertheless, important uncertainties remain. Long-term pediatric-specific safety data are still limited, particularly regarding prolonged eosinophil modulation during critical phases of immune and airway development. In addition, current studies are underpowered to detect rare adverse events and provide limited insight into very long treatment durations, treatment interruption and re-initiation, or the safety of sequential biologic use after switching. Accordingly, continued post-marketing surveillance and prospective longitudinal pediatric cohorts will be essential to further define the long-term safety profile of mepolizumab in routine practice. Limitations and Knowledge Gaps Despite its growing integration into pediatric severe asthma care, the evidence base for mepolizumab in children and adolescents remains substantially more limited than that available in adults. A major constraint is the scarcity of pediatric randomized controlled trials. To date, the most robust efficacy signal derives from a single dedicated placebo-controlled pediatric trial,56 whereas approval in younger children was largely supported by extrapolation from adult and adolescent data together with pediatric pharmacokinetic and pharmacodynamic bridging studies.54,55 Although this strategy is scientifically reasonable and commonly adopted in pediatric drug development, it inevitably limits the strength of pediatric-specific conclusions regarding the full range of clinical outcomes.65 A second major limitation is the relative inconsistency of outcome domains beyond exacerbation reduction. Across the available pediatric literature, mepolizumab demonstrates a clear effect on blood eosinophils and a clinically relevant effect on exacerbation burden, yet improvements in lung function, daily symptom control, and composite severity indices are less uniform.54–56 This raises an important conceptual issue: the endpoints that best capture response in adults may not fully reflect treatment benefit in children, where disease expression is influenced by developmental, environmental, and behavioral factors, and where exacerbation-prone disease may be more clinically informative than baseline spirometric impairment alone. Another important gap concerns patient selection and biomarker refinement. Current eligibility criteria and response assessment are still driven largely by blood eosinophil thresholds and exacerbation history, but pediatric studies increasingly suggest that these measures do not fully capture the heterogeneity of airway inflammation in childhood severe asthma. Mechanistic analyses from MUPPITS-2 indicate that residual disease during mepolizumab treatment may be sustained by activated airway eosinophil subsets, epithelial inflammatory programs, macrophage-associated pathways, and persistent non-eosinophilic gene networks.56–59 These findings imply that eosinophil counts alone are insufficient to define the biology of incomplete response and highlight the need for more precise pediatric biomarkers capable of identifying which children are most likely to derive sustained benefit from IL-5 blockade. The available real-world literature also highlights important methodological and clinical gaps. Most observational pediatric studies remain retrospective, relatively small, and heterogeneous in design, with variable definitions of response, inconsistent follow-up duration, and limited standardization of outcome reporting. In addition, registry and real-world cohorts reveal that many children remain partly controlled or uncontrolled despite biologic treatment, and switching between biologics is not uncommon.60–63 These observations are clinically important because they suggest that routine care increasingly involves sequential biologic decision-making, yet the evidence base to guide such choices remains weak. Head-to-head comparative data are especially lacking. In contemporary pediatric practice, multiple biologics may be suitable for the same patient, particularly in children with overlapping allergic and eosinophilic features. However, direct comparative evidence remains sparse, and treatment selection is still based largely on phenotype, biomarker profile, prior biologic exposure, local access criteria, and clinician experience rather than on definitive comparative pediatric data. This remains one of the most important unmet needs in the field, particularly as switching and sequential biologic use become more common. Long-term pediatric safety and disease-modifying effects also remain incompletely defined. Although short- and medium-term pediatric safety findings are reassuring, and adult-dominant long-term extension data support overall tolerability over many years, pediatric-specific long-term datasets remain too small to answer several clinically relevant questions with confidence. These include the consequences of prolonged eosinophil suppression during childhood, the optimal duration of therapy, the effects of treatment interruption or discontinuation, and the possibility that early biologic intervention could modify disease trajectory or limit airway remodeling over time.66,67 Finally, there is still no consensus on how best to define response, partial response, or remission in children receiving mepolizumab. A multidimensional framework that incorporates exacerbations, corticosteroid burden, healthcare utilization, symptom control, lung function, and patient-reported outcomes is likely to be more informative than reliance on any single marker alone.68 Future pediatric studies should therefore move beyond simple eosinophil-based selection and aim to integrate clinical, functional, and mechanistic measures in order to better individualize treatment and identify nonresponders early. Taken together, these limitations do not weaken the clinical relevance of mepolizumab in pediatric severe eosinophilic asthma, but rather define the priorities for the next phase of research. Larger prospective pediatric cohorts, more standardized real-world outcome frameworks, deeper endotype characterization, and comparative biologic studies will be essential to optimize patient selection, refine treatment goals, and clarify the long-term place of mepolizumab within precision medicine for childhood severe asthma. Conclusions and Future Perspectives Mepolizumab represents an important advance in the treatment of children and adolescents with severe eosinophilic asthma, offering a biologically targeted strategy directed at the IL-5/eosinophil axis, a central pathway in type 2 airway inflammation. The available pediatric evidence consistently supports its ability to reduce exacerbation burden, decrease oral corticosteroid exposure, and provide clinically meaningful benefit in a substantial proportion of patients, while maintaining a generally favorable safety and tolerability profile. At the same time, the current evidence base remains smaller and less mature than that available in adults, and important aspects of pediatric use still rely on pharmacologic bridging, mechanistic plausibility, and relatively limited disease-specific datasets. A key message emerging from recent pediatric studies is that treatment response to mepolizumab cannot be fully explained by blood eosinophil suppression alone. Mechanistic analyses indicate that persistent airway eosinophil subsets, epithelial inflammatory programs, macrophage-associated pathways, and other noncanonical inflammatory circuits may contribute to residual disease activity and breakthrough exacerbations despite effective IL-5 blockade. These findings reinforce the need to move beyond simple biomarker thresholds toward a more nuanced, multidimensional approach to patient stratification and response assessment in childhood severe asthma. Future research should therefore prioritize the identification and validation of pediatric-specific predictors of response, including biomarkers capable of capturing airway biology more accurately than peripheral eosinophil counts alone. Equally important will be the development of standardized outcome frameworks that integrate exacerbations, corticosteroid burden, symptom control, healthcare utilization, lung function, and patient-reported outcomes. Longer-term studies are also needed to clarify whether sustained IL-5 inhibition can modify lung function trajectories, reduce airway remodeling, or influence the natural history of severe asthma during critical phases of lung development. Several clinically relevant questions remain unresolved, including the optimal duration of therapy, the criteria for treatment continuation or withdrawal, and the positioning of mepolizumab relative to other available biologics in children with overlapping allergic and eosinophilic phenotypes. In the absence of head-to-head pediatric trials, biologic selection currently relies primarily on phenotype, biomarker profile, relevant comorbidities, regulatory eligibility, previous treatment response, and clinical judgment. In this context, ongoing prospective studies, including long-term observational cohorts and comparative trials, are expected to provide important insight into long-term effectiveness, treatment persistence, and biologic selection in pediatric severe asthma.69,70 Overall, current evidence supports mepolizumab as a valuable component of precision medicine for pediatric severe eosinophilic asthma, particularly in children with recurrent exacerbations and significant corticosteroid burden. The next challenge is not simply to confirm efficacy, but to understand which child benefits most, how treatment should be monitored over time, and whether earlier and more individualized intervention can ultimately alter long-term respiratory outcomes. Funding Statement No funding was received for this article. Data Sharing Statement Data sharing is not applicable to this article as no data were created or analysed in this study. Author Contributions Marta Bajeli: Conceptualization; Investigation; Literature analysis; Writing – original draft; Writing – review and editing. Antonio Corsello: Conceptualization; Investigation; Literature analysis; Writing – original draft; Writing – review and editing. Simone Foti Randazzese: Investigation; Literature analysis; Writing – original draft; Writing – review and editing. Alessia Marseglia: Investigation; Literature analysis; Writing – review and editing. Paola D’Agostino: Investigation; Literature analysis; Writing – review and editing. Carlo Maria Rossi: Investigation; Literature analysis; Writing – review and editing. Gian Luigi Marseglia: Conceptualization; Supervision; Validation; Writing – review and editing. Amelia Licari: Conceptualization; Methodology; Supervision; Validation; Writing – original draft; Writing – review and editing. All authors made a significant contribution to the work reported, whether in the conception, study design, literature analysis, drafting, revision, or supervision of the article. All authors gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors report no conflicts of interest in this work. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no data were created or analysed in this study.